CClinicalTrials.gg
Sign In
Status unknownNCT05470426Updated Jul 22, 2022

Viral Excretion Among COVID-19 Omicron Recurrence Patients

An observational study in COVID-19 Recurrence and Surface Contamination, sponsored by RenJi Hospital. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by RenJi Hospital · Observational

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Sex
All
01

Study summary

The study analyzes the viral nucleic acid excretion and its influencing factors of SARS-COV-2 Omicron recurrence patients.

02

Conditions studied

  • COVID-19 Recurrence
  • Surface Contamination
03

In context

COVID-19

7,641 studies on the registry are indexed under COVID-19; 487 are open to participants now.

This study's planned enrollment of 35 is below the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with COVID-19 Omicron Recurrence

Inclusion criteria

  • Patients with nucleic acid detection N gene and ORF gene Ct value \< 40 after discharge from hospital
  • Being able to provide basic information, living habits, vaccination information, admission information

Exclusion criteria

Exclusion Criteria:

  • Single gene target positive
  • Patients with incomplete baseline data
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Interventions

  • OtherCOVID-19 Omicron Recurrence

    COVID-19 Omicron Recurrence

06

What researchers measure

Primary outcomes

  1. COVID-19 Omicron Recurrence

    COVID-19 Omicron Recurrence

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
  • Renji Hospital
    Shanghai, 200123, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05470426
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Jul 2022 (estimated)
Primary completion
Jul 2023 (estimated)
Completion
Aug 2023 (estimated)
Last update
Jul 22, 2022

Study contacts

Ya Yang, PhD
Contact
yangya@renji.com
68383362

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19→

Other studies from this sponsor

RenJi Hospital

Start the discussion